3SBio (1530) AI Stock Analysis

• Market Cap: $75.70B
• Dividend Yield: 0.79%
• Average Volume (3M): 31.12M
• Price to Earnings (P/E): 29.1
• Beta (1Y): 0.96
• Revenue Growth: 7.51%
• EPS Growth: 44.09%
• Country: HK
• Employees: 5,577
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.62
• Shares Outstanding: 2,432,594,000
• 10 Day Avg. Volume: 32,899,411
• 30 Day Avg. Volume: 31,124,824
• PEG Ratio: 0.16
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 1.54
• P/FCF Ratio: 6.27
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 6.12
• Enterprise Value/Gross Profit: 7.17
• Enterprise Value/Ebitda: 20.64
• 1Y Price Target: $42.66
• Price Target Upside: 45.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: HK$32.00 ▲(9.22% Upside)

3SBio's overall stock score is driven by its strong financial performance, characterized by robust revenue and profit growth. However, technical indicators suggest potential short-term weakness, and the high valuation may limit upside potential. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth over multiple years indicates a strong market position and effective business strategy, supporting long-term sustainability.

Profitability

Improving net profit margins reflect efficient cost management and strong operational performance, enhancing the company's financial resilience.

Balance Sheet Stability

A decreasing debt-to-equity ratio signals improved financial stability, providing a strong foundation for future growth and investment.

Negative Factors

Cash Flow Consistency

Inconsistent free cash flow growth can pose risks to liquidity and limit the company's ability to invest in new opportunities or weather economic downturns.

Liabilities Increase

Rising liabilities may strain financial resources and necessitate careful management to avoid potential solvency issues.

Cash Flow Data Limitations

Lack of recent cash flow data hampers comprehensive financial analysis, potentially obscuring liquidity challenges or operational inefficiencies.

3SBio Business Overview & Revenue Model

Company Description

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

How the Company Makes Money

3SBio generates revenue through multiple streams, primarily by selling its proprietary biopharmaceutical products to hospitals and healthcare providers in China. The company earns significant income from the sales of its key products, including its flagship drug, EPO, which is used to treat anemia in patients with chronic kidney disease and cancer. Additionally, 3SBio engages in strategic partnerships and collaborations with other pharmaceutical companies for the development and commercialization of new therapies, which may involve upfront payments, milestone payments, and royalties on sales. The company also invests in research and development to innovate and expand its product pipeline, which can lead to increased market share and revenue growth over time.

3SBio Financial Statement Overview

Summary

3SBio demonstrates robust financial health with strong revenue and profit growth, a solid balance sheet, and effective cash management. However, challenges in cash flow consistency due to investment activities need to be addressed to maintain long-term financial strength.

Income Statement

3SBio shows a strong income statement with consistent revenue growth from 2019 to 2024. The gross profit margin is robust, indicating efficient cost management, and the net profit margin has improved significantly over the years, demonstrating enhanced profitability. The EBIT and EBITDA margins are healthy, showcasing strong operational performance.

Balance Sheet

The balance sheet reflects a solid equity base with a decreasing debt-to-equity ratio over the years, signaling improved financial stability. Return on Equity (ROE) is strong, indicating effective utilization of equity. The equity ratio indicates a sound proportion of assets funded by equity, although the increase in total liabilities in recent years suggests a need for cautious financial management.

Cash Flow

Cash flow from operations has been positive, reflecting good cash management and business operations. However, the free cash flow growth is inconsistent due to fluctuating capital expenditures and investing cash flows, which may pose a risk to liquidity. The operating cash flow to net income ratio indicates healthy cash conversion, but the absence of 2024 cash flow data limits full analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.07B	9.11B	7.82B	6.86B	6.38B	5.59B
Gross Profit	7.75B	7.83B	6.64B	5.67B	5.28B	4.52B
EBITDA	2.69B	2.93B	2.53B	2.75B	2.26B	1.68B
Net Income	2.36B	2.09B	1.55B	1.92B	1.65B	835.79M
Balance Sheet
Total Assets	23.83B	24.21B	23.63B	21.99B	19.21B	17.68B
Cash, Cash Equivalents and Short-Term Investments	6.46B	5.79B	5.99B	7.01B	4.70B	4.36B
Total Debt	1.87B	3.55B	4.84B	4.52B	2.63B	2.91B
Total Liabilities	4.89B	6.18B	7.11B	6.59B	4.55B	4.58B
Stockholders Equity	16.32B	15.44B	14.03B	12.96B	12.23B	10.69B
Cash Flow
Free Cash Flow	1.67B	2.24B	1.38B	1.21B	432.57M	363.09M
Operating Cash Flow	2.11B	3.20B	2.08B	2.18B	1.58B	1.34B
Investing Cash Flow	-738.83M	-1.36B	-1.35B	-3.72B	-1.29B	-1.87B
Financing Cash Flow	-1.28B	-2.25B	-352.98M	763.22M	-481.12M	1.55B

3SBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.30
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Negative. The current price of 29.3 is below the 20-day moving average (MA) of 31.18, below the 50-day MA of 30.01, and above the 200-day MA of 22.42, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 47.75 is Neutral, neither overbought nor oversold. The STOCH value of 47.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1530.

3SBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1530	68 Neutral	$75.70B	29.10	15.34%	0.79%	7.51%	44.09%
2696	66 Neutral	HK$34.13B	38.35	27.37%	―	2.57%	18.79%
2269	63 Neutral	$130.61B	28.53	9.79%	―	16.90%	63.11%
1801	61 Neutral	$148.82B	116.92	8.41%	―	52.78%	―
1177	54 Neutral	$124.66B	31.23	11.72%	1.30%	13.69%	50.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1877	43 Neutral	HK$36.44B	-23.10	-15.06%	―	39.02%	48.26%

3SBio Corporate Events

3SBio Announces Proposed Spin-Off and Listing of Mandi Inc.

3SBio, a company incorporated in the Cayman Islands, has announced its intention to spin-off and separately list its subsidiary, Mandi Inc., on the Main Board of the Stock Exchange of Hong Kong. This strategic move involves distributing all shares of Mandi held by 3SBio to its shareholders and offering new shares through a global offering. The spin-off aims to allow Mandi to operate independently, with 3SBio ceasing to hold any interest in it post-listing. The proposal is subject to regulatory approvals and market conditions, and stakeholders are advised to exercise caution as the spin-off may not proceed.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$38.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Subsidiary Mandi Inc. Issues Shares Under Equity Incentive Plan

3SBio’s subsidiary, Mandi Inc., has announced the issuance of 640 shares as part of its equity incentive plan to reward directors, senior management, and employees for their contributions. This move will slightly reduce 3SBio’s effective interest in Mandi from 100% to 93.6%, but Mandi will remain a subsidiary. The issuance is seen as a strategic step to sustain business stability and recognize past contributions, aligning with the company’s long-term interests.

The most recent analyst rating on (HK:1530) stock is a Hold with a HK$32.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio, Inc. Reports Strong Net Profit Growth

3SBio, Inc., a leading biotechnology company based in the Cayman Islands, specializes in the development, production, and sale of biopharmaceutical products, primarily serving the healthcare sector in Mainland China. The company is recognized for its innovative products, including TPIAO, the only commercialized recombinant human thrombopoietin worldwide.

3SBio Reports Increased Profits Despite Revenue Dip in H1 2025

3SBio reported its interim financial results for the first half of 2025, showing a slight decrease in revenue by 0.8% to RMB4,355.5 million compared to the same period in 2024. Despite this, the company achieved a significant increase in net profit attributable to owners by 24.6% to RMB1,358.2 million, driven by other income and gains, and a reduction in finance costs. The results indicate a strong operational performance despite a challenging market environment, with implications for improved profitability and stakeholder confidence.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.